Turning Point Brands (TPB) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
2 Mar, 2026Executive summary
Q4 net sales rose 29% year-over-year to $121 million, driven by 266% growth in Modern Oral segment, now 34% of total sales.
Adjusted EBITDA increased 14% to $30 million in Q4, with a margin of 24.8%.
Full-year 2025 net sales reached $463.1 million, with net income up 46.1% to $58.2 million.
White pouch brands FRĒ and ALP saw significant sales growth and expanded distribution.
Strategic investments prioritized Modern Oral, while legacy brands continued to generate strong cash flow.
Financial highlights
Q4 revenue: $121 million, up 29% year-over-year; Modern Oral net revenue: $41.3 million, up 266% year-over-year.
Stoker's segment Q4 net sales: $81 million, up 70% year-over-year; Zig-Zag segment Q4 net sales: $40 million, down 13%.
Q4 gross profit: $67.7 million, up 29.1%; gross margin: 55.9%, flat versus last year.
Free cash flow: $19.2 million; CapEx: $3.3 million for Q4; ending cash at $222.8 million.
Q4 SG&A expenses increased 38.2% year-over-year to $47.7 million, driven by Modern Oral investments and higher freight costs.
Outlook and guidance
FY 2026 Modern Oral gross revenue guidance: $220–$240 million; net revenue: $180–$190 million.
Q1 2026 Adjusted EBITDA expected between $24 million and $27 million, including continued Modern Oral investment.
Effective income tax rate projected at 23%–26% going forward.
2026 CapEx budgeted at $4–$5 million, plus $3–$5 million for Modern Oral PMTAs.
Latest events from Turning Point Brands
- Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 20242 Feb 2026 - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 202415 Jan 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor change, officer liability limits, and executive pay approval.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025 - Modern Oral sales soared 628% year-over-year, driving record Q3 growth and raised guidance.TPB
Q3 202513 Nov 2025